Sorrento Therapeutics Announces the FDA IND Clearance of
STI-1558, an oral SARS-CoV-2 main protease inhibitor which can block viral replication, is specifically designed as a standalone treatment of COVID-19.Studies to date indicate that STI-1558 does not require the ...